



Final Appraisal Recommendation

Advice No: 1219 – October 2019

Zanamivir (Dectova®) 10 mg/ml solution for infusion

Limited submission by GlaxoSmithKline UK

Recommendation of the All Wales Medicines Strategy Group

Zanamivir (Dectova®) is recommended as an option for use within NHS Wales for the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ≥ 6 months) when: the patient's influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/or other anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient. Zanamivir (Dectova®) should be used in accordance with official guidance.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 4130), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

The All Wales Therapeutics and Toxicology Centre (AWTTC) reviewed this appraisal recommendation in December 2022. It will be reviewed again in three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 1219: zanamivir (Dectova®) 10 mg/ml solution for infusion October 2019